Visioneering Technologies (ASX: VTI) Share Price and News

Ms. Miller has over 30 years of leading and advising boards of public and high-growth companies on finance, accounting, compensation, mergers & acquisitions, initial public offerings, governance, strategy and operations. Ms. Miller currently serves as a Non executive Director and Audit Committee Chair for Tecsys (TO:TCS), a supply chain and complex distribution management system provider; Audit Committee Chair for True Commerce, a private equity backed leader in EDI and multi-enterprise supply chain eCommerce and business networks; and Non-executive Director for TeamFront, a united team of software companies and vertical SaaS experts on the frontline of everyday industries. Prior to her retirement, Ms. Miller was CFO of Nitro Software, Inc., a high growth SaaS-based workflow productivity company, where she contributed to 200% recurring revenue CAGR and 95% client retention. Through her CFO role and at the board level, she led the ASX IPO for this $40M business. Previously, Ms. Miller led dual roles as CFO and COO of nCourt LLC, a high-growth SaaS-based software and payment service provider with $4B+ in processed funds, overseeing all operational and financial functions. She is chair of risk committee.

Mr. Silverberg has over 20 years of experience as an investor and leader in the global money management industry and possesses expertise and relationships in investment management, capital markets, and investment banking. Mr. Silverberg currently serves as an Investment Manager with Thorney Investment Group Australia Pty Ltd. From 2014 to 2017, Mr. Silverberg served as Senior Portfolio Manager at Talpion Fund Management, a New York based family office, where he managed a global equity portfolio and researched public and private investment opportunities. From 2012 to 2014, Mr. Silverberg re-joined hedge fund firm Mark Asset Management as Partner and Portfolio Manager. From 2001 - 2012, Mr. Silverberg was a Senior Vice President and Portfolio Manager with institutional money management firm Fred Alger Management. Mr. Silverberg began his career as a Research Analyst with Mark Asset Management. He is Member of the Risk Committee.

Dr. Akerman is an executive in the vision care industry, with over 40 years of leadership in optometry, new product development, clinical and regulatory affairs, academic and professional affairs, business development and licensing, and executive management. He is currently the Chief Medical Editor of the publication Review of Myopia Management. From 2001 to 2011 at Ciba Vision, he served as Director of Marketing, Director of Professional Affairs in North and South America, and Global Head of Medical Affairs at Novartis Ophthalmics. Then, after Ciba Vision merged with Alcon, he served as Executive Director of U.S. Professional Affairs before being promoted to Vice President and Global Head of Professional Affairs and Business Development. In this last role at Alcon, Dr. Akerman was a member of the vision care global leadership team and had responsibilities for myopia management strategy, medical marketing, business development and licensing, and managed the company's relationship with global medical associations. He retired from Alcon in 2019. He is Chair of the Science and Technology Committee and member of the Risk Committee.

Dr. Rubenstein is experienced public company board director and an entrepreneur. He served for 29 years on the board of The Cooper Companies, Inc. (NYSE: COO), including as either Chairman or Lead Independent Director for all but two of those years. The Cooper Companies, Inc. is the parent company of CooperVision. Dr. Rubenstein founded, grew, and sold a mobile CT and MRI scanning company. He then founded and served as CEO of NexGenix Pharmaceuticals, which developed drugs for cancer and genetic disorders. NexGenix was acquired by Oncosynergy in 2011. He was a board member of Bioclinica (Nasdaq: BIOC), which provided imaging services for clinical trials (Bioclinica merged in 2021 to become Clario, a private company). He was the Chairman of the Scientific Advisory Board (SAB) for Plex Pharmaceuticals, a privately held biotechnology company, for 9 years and presently is the head of the SAB for 2 privately held companies in the vision space: Coloursmith Labs and EyeVision Pharma. He is also a member of the advisory board for the Tufts University Graduate School of Biomedical Sciences, a program that engages stakeholders from science, private equity and governmental sectors to commercialize advances in medicine and is Chairman Emeritus of the SAB for the Children's Tumor Foundation, which he co-founded. Dr. Rubenstein is currently Clnical Professor of Neurology and Pediatrics at NYU Medical Center. He is member of the Science and Technology Committee.

Dr. Aragon brings over 30 years of leadership in the vision care industry to VTI. His experience includes senior executive leadership positions in international vision care companies, as well as managing divisions for the Americas, Asia Pacific, and Europe. Most recently, he was President of CooperVision (CV) Specialty EyeCare, which incorporates CV's soft custom and rigid gas permeable contact lens product offerings, including orthokeratology, scleral lenses, and myopia management products for global markets, including China. In the previous 23 years, Dr. Aragon has held positions within CooperVision and a predecessor company. He also held positions within CIBA Vision, a predecessor company to Alcon, and with Bausch plus Lomb. Dr. Aragon earned his optometry degree from the Superior School of Medicine of the National Polytechnic Institute in Mexico City. Dr. Aragon is a former board member and former Chair of the Global Myopia Awareness Coalition (GMAC), a group of leading companies working together to protect children from the effects of myopia. His leadership in and service to GMAC highlights Dr. Aragon's dedication to vision care and the respect the industry has for his capabilities. He also volunteers as Chairman of the Board of Optometry Giving Sight; and has been a board member of the Brien Holden Foundation, the International Agency for the Prevention of Blindness, and Vision Aid Overseas (now Vision Action). He was also a Board Member of Sight Glass Vision, now a Joint Venture of CooperVision and Essilor/Luxottica.

-

-

-

-